Advertisement
Product › Details
DNA Damage Response (DDR) cancer therapy
Next higher product group | cancer drug | |
Status | 2016-09-21 development existent | |
Organisation | Artios Pharma Ltd. | |
Record changed: 2023-07-10 |
Advertisement
More documents for DNA Damage Response (DDR) cancer therapy
- [1] Nodus Oncology Ltd.. (9/6/22). "Press Release: Nodus Oncology Launches, Founded by Cumulus Oncology and in Partnership with the Lead Discovery Center, to Focus on Developing First and Best-in-Class Molecules Inhibiting Novel DNA Damage Response Targets"....
- [2] Nodus Oncology Ltd.. (9/6/22). "Press Release: Nodus Oncology Announces Acquisition of Basilea Pharmaceutica’s PARG Inhibitor Programme". Edinburgh....
- [3] Artios Pharma Ltd.. (7/27/21). "Press Release: Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X". Cambridge & New York, NY....
- [4] Artios Pharma Ltd.. (4/7/21). "Press Release: Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies". Cambridge & New York, NY....
- [5] Artios Pharma Ltd.. (1/12/21). "Press Release: Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer". Cambridge & New York, NY....
- [6] Exscientia Ltd.. (9/9/20). "Press Release: Huadong Medicine and Exscientia Enter Co-development Partnership to Accelerate Oncology Drug Discovery through Artificial Intelligence"....
- [7] Artios Pharma Ltd.. (11/6/19). "Press Release: Artios Pharma, MD Anderson and ShangPharma Announce In-licensing Agreement for DNA Damage Response Inhibitor". Cambridge, New York, NY, Houston, TX & South San Franicsco, CA....
- [8] Artios Pharma Ltd.. (9/24/19). "Press Release: Artios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States". Cambridge & New York, NY....
- [9] Evotec SE. (7/8/19). "Press Release: Evotec and Venture Capital Consortium Form Breakpoint Therapeutics GmbH". Hamburg....
- [10] Artios Pharma Ltd.. (8/10/18). "Press Release: Artios Pharma Announces $84 million (£65 million) Series B Financing. Financing Round Led by New Investors Andera Partners and LSP"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top